chief executive officer & board member
Over 25 years in the pharmaceutical industry specializing in business development, corporate strategy and operational efficiency. Mr. Prygocki was President of Medicis Pharmaceutical Corporation. He was employed with Medicis from 1991 until its acquisition in 2012. Currently acting as a board member and consultant to the pharmaceutical industry and operating several privately-held retail companies.
Director, Chairman, Audit Committee of the Board of Directors, Revance Therapeutics, Inc. May 2014-Present. Director, Chairman, Audit Committee of the Board of Directors, Clarus Therapeutic, Inc. July 2014-Present. Prior to joining Medicis; employed by Citigroup, an investment banking firm, in the regulatory reporting division, and by Ernst & Young, LLP, in the auditing department. Served for greater than 10 years on the Board of Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs.
Chairman of the Board
Jonah Shacknai serves as Executive Chairman of DermaForce Partners, an aesthetics technology firm that develops and globally commercializes novel cosmetic and OTC products in multiple channels, including the new doctor-dispensed skincare brand SkinBetter Science. Prior to co-founding DermaForce, Mr. Shacknai was the founder, Chairman, and Chief Executive Officer of Medicis Pharmaceuticals Corporation. Mr. Shacknai has an extremely well diversified public service, law and corporate background, with vast experience and expertise in the pharmaceutical and healthcare industries.
Throughout his distinguished career, Mr. Shacknai has been honored with a Doctorate of Humane Letters by an affiliate of Columbia University College of Physicians & Surgeons, the “National Award” from the Freedoms Foundation at Valley Forge, “Entrepreneurial Fellow” at the Karl Eller Center of the University of Arizona, the “President's Award” from the American Society for Dermatologic Surgery, and “Lifetime Achievement” awards from several dermatology institutions.
Currently, Mr. Shacknai serves as Co-Chaiman of the Foundation Board of the Campaign for Tobacco-Free Kids, Vice President of the Board of Directors of the Campaign for Tobacco Free Kids, and President of the MaxInMotion® Foundation, a non-profit organization assisting economically challenged and student athletes with disabilities. Mr. Shacknai earned a B.S. degree from Colgate University, and a J.D. from Georgetown University Law Center.
DR. JACOB WAUGH
ILLUSTRIS FOUNDER, CHIEF SCIENTIFIC OFFICER & BOARD MEMBER
Dr. Waugh is the Founder, Chief Scientific Officer, Medical Director, and a member of the board of directors of Illustris Pharmaceuticals, Inc. He has over 26 years of experience in applied cross-disciplinary research. He is the Co-Founder of Revance Therapeutics. He trained with pioneering leaders in molecular medicine and chemistry, has received numerous awards, and has authored over 40 research manuscripts and publications.
Dr. Waugh served as a Senior Scientist at Stanford University School of Medicine from 2001 to 2004, where he pioneered in vivo tissue engineering applications. Dr. Waugh has also served as an advisor in the medical device and pharmaceutical industries as well as a reviewer for number of prominent scientific and medical journals.
DR. S.K. TAN
Dr. Tan is one of the foremost physicians in aesthetics and cosmeceuticals in Asia. Hegraduated from medical school in 1971 and his interest in dermatology led him to train at the prestigious St. John's Institute of Dermatology in London in the 1970's. He has postgraduate qualifications in dermatology and venereology and has an MBA from the Maastricht Business School (Holland), and also has a Diploma in Cosmetic Science (London).
He has been focused in the field of aesthetic dermatology and was a founding member of Derma-Rx and The DRx Clinic before setting up the IDS Clinic and launching the IDS range of skincare products.
He is a Fellow of the American Academy of Dermatology (FAAD) and a member of numerous Cosmetic Dermatology-related associations. He has published in numerous international dermatology and cosmetic dermatology journals and has clinical and research interests in pigmentary disorders and acne.
As Head of Investment Banking at Triad Securities Corporation, Mr. Hirschberg is focused on M&A and Strategic life science transactions within the specialty pharmaceutical sector. Prior to joining Triad Securities, Mr. Hirschberg served as Managing Director at Roberts Mitani, LLC from July 2011 through December 2013. From May 1984 through June 2011, Mr. Hirschberg served as President of Corporate Development Specialists Inc., a firm which provided advisory services to pharmaceutical, device, consumer and biomedical companies.
Mr. Hirschberg received a B.A. from Colgate University, a Masters in Accounting from NYU Stern School of Business, and an MBA from University of Chicago Graduate School of Business.